Economic burden and treatment equity in high-efficacy multiple sclerosis therapies after the Inflation Reduction Act: formulary design, extended-interval dosing, and biomarker-guided stewardship
Economic burden and treatment equity in high-efficacy multiple sclerosis therapies after the Inflation Reduction Act: formulary design, extended-interval dosing, and biomarker-guided stewardship. // Equity Neuroscience. – URL: https://www.sciencedirect.com/science/article/pii/S305084012600053X?dgcid=rss_sd_all
Economic burden and treatment equity in high-efficacy multiple sclerosis therapies after the Inflation Reduction Act: formulary design, extended-interval dosing, and biomarker-guided stewardship. Equity Neuroscience. https://www.sciencedirect.com/science/article/pii/S305084012600053X?dgcid=rss_sd_all
“Economic burden and treatment equity in high-efficacy multiple sclerosis therapies after the Inflation Reduction Act: formulary design, extended-interval dosing, and biomarker-guided stewardship.” Equity Neuroscience.
@article{article8746,
title = {Economic burden and treatment equity in high-efficacy multiple sclerosis therapies after the Inflation Reduction Act: formulary design, extended-interval dosing, and biomarker-guided stewardship},
journal = {Equity Neuroscience},
url = {https://www.sciencedirect.com/science/article/pii/S305084012600053X?dgcid=rss_sd_all}
}